



GLAND PHARMA LIMITED

August 01, 2025

BSE Limited
Surveillance Department
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Surveillance Department
Exchange Plaza, Bandra Kurla Complex Bandra (East),
Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Response to the National Stock Exchange of India Limited's letter (NSE/CM/Surveillance/15698) and BSE Limited's letter (L/SURV/ONL/RV/AJ/ (2025-2026)/ 50), in each case dated August 1, 2025

This is with reference to the National Stock Exchange of India Limited's ("NSE") letter (NSE/CM/Surveillance/15698) and BSE Limited's ("BSE") letter (L/SURV/ONL/RV/AJ/ (2025-2026)/ 50), in each case dated August 1, 2025 in relation to a recent news item which appeared in the "www.moneycontrol.com" dated August 01, 2025 captioned "Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices" ("New Article").

Please see below the Company's responses in relation to the queries raised by the NSE and BSE:

a) ***Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.***

The Company is not a recipient of the communication referenced in the News Article.

b) ***Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.***

The Company does not have any undisclosed / potentially price sensitive information / event / announcement to be shared with the Stock Exchanges under Regulation 30 of SEBI (LODR) Regulations, 2015 for the captioned subject.

c) ***The material impact of this article on the Company.***

The decrease in the share price of the Company may be attributed to the general market conditions in line with the decline in Healthcare / Pharma Indices.

d) ***In case of regulatory/legal proceedings please provide the information on initiation / outcome of the proceedings.***

Not applicable.

The Company remains committed to ensuring the highest standards of compliance and transparency in all its disclosures. We request you to take the above on record and treat the same as compliance under the applicable provisions of the Listing Regulations.

Thanking You.

Please take the same on record.

Yours truly,
For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer